PSNL Profile
Personalis Inc. (PSNL) is a company that provides genomic analysis services to cancer researchers and medical institutions. The company uses advanced sequencing technologies and artificial intelligence to analyze large amounts of genomic data, helping its clients to make informed decisions about the development of personalized cancer treatments.
Personalis offers a range of services, including whole exome sequencing, tumor sequencing, RNA sequencing, and immune cell profiling. These services are designed to help researchers and clinicians identify the genetic mutations and other molecular changes that drive cancer growth, as well as to identify potential targets for new cancer therapies.
The company's platform is built on a proprietary database of genomic information, called the ImmunoID NeXT Platform. This platform enables Personalis to provide its clients with detailed genomic data that is tailored to their specific research needs. Personalis also offers bioinformatics and consulting services to help its clients interpret the genomic data and make informed decisions about the development of new cancer treatments.
Personalis was founded in 2011 and is headquartered in Menlo Park, California. The company went public in 2019 and is traded on the NASDAQ stock exchange under the ticker symbol PSNL.
|
